Hefei Huafang Pharmaceutical Technology

Hefei Huafang Pharmaceutical Technology is a Chinese pharmaceutical company established in December 2003 and based in the Hefei National High-tech Zone. The company specializes in the research, development, and industrialization of advanced drug delivery systems (DDS), with a particular focus on osmotic pump controlled-release formulations, oral fast-dissolving formulations, and liposomes. Its commercial portfolio includes Xinleding (venlafaxine hydrochloride sustained-release tablets), Meiloding (nifedipine controlled-release tablets), and doxazosin mesylate sustained-release tablets, which leverage its proprietary osmotic pump technology to achieve stable blood drug concentrations and improve patient compliance. Hefei Huafang operates multiple GMP production platforms through its subsidiaries and contract manufacturing partners, positioning itself as a high-tech enterprise in the high-end formulation sector.